Evidence map›Paper›PMID 34724985›Full record

ArticleMilitary Medical Research2021

Common mtDNA variations at C5178a and A249d/T6392C/G10310A decrease the risk of severe COVID-19 in a Han Chinese population from Central China.

Yi Wu, Xian-Hui Wang, Xi-Hua Li, Li-Yuan Song, Shi-Long Yu, Zhi-Cheng Fang, Yu-Quan Liu, Le-Yong Yuan, Chun-Yan Peng, Shen-Yi Zhang and 6 more

Abstract read
In one paragraph

Article in Military Medical Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Post-Acute Sequelae and Mitochondrial Aberration in SARS-CoV-2 Infection.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yi Wu *Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Xian-Hui Wang *Institute of Biomedical Research, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Xi-Hua Li *Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Li-Yuan SongDepartment of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Shi-Long YuInstitute of Human Respiratory Disease, Xinqiao Hospital, The Army Medical University (Third Military Medical University), 400037, Chongqing, China.
Zhi-Cheng FangDepartment of Emergency Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Yu-Quan LiuDepartment of Geriatric Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Le-Yong YuanDepartment of Immunology, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Chun-Yan PengDepartment of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Shen-Yi ZhangDepartment of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Wang ChengDepartment of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Hong-Chao MaDepartment of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Li-Feng WangDepartment of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Jun-Ming TangHubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China. tangjm416@163.com.
Yun-Fu WangDepartment of Neurology, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China. wangyunfu@hbmu.edu.cn.
Fu-Yun JiDepartment of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China. jifuyun@263.net.ORCID 0000-0002-5026-1861

Funding

the Cultivating Project for Young Scholar at Hubei University of Medicine №: 2018QDJZR01the Special Project of Contingency Research for COVID-19 at Hubei University of Medicine №:2020XGFYZR03the Special Project of Contingency Research for COVID-19 at Hubei University of Medicine №:2020XGFYZR11
6 · The paper itself

Abstract

backgroundMitochondria have been shown to play vital roles during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) development. Currently, it is unclear whether mitochondrial DNA (mtDNA) variants, which define mtDNA haplogroups and determine oxidative phosphorylation performance and reactive oxygen species production, are associated with COVID-19 risk.

methodsA population-based case-control study was conducted to compare the distribution of mtDNA variations defining mtDNA haplogroups between healthy controls (n = 615) and COVID-19 patients (n = 536). COVID-19 patients were diagnosed based on molecular diagnostics of the viral genome by qPCR and chest X-ray or computed tomography scanning. The exclusion criteria for the healthy controls were any history of disease in the month preceding the study assessment. MtDNA variants defining mtDNA haplogroups were identified by PCR-RFLPs and HVS-I sequencing and determined based on mtDNA phylogenetic analysis using Mitomap Phylogeny. Student's t-test was used for continuous variables, and Pearson's chi-squared test or Fisher's exact test was used for categorical variables. To assess the independent effect of each mtDNA variant defining mtDNA haplogroups, multivariate logistic regression analyses were performed to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) with adjustments for possible confounding factors of age, sex, smoking and diseases (including cardiopulmonary diseases, diabetes, obesity and hypertension) as determined through clinical and radiographic examinations.

resultsMultivariate logistic regression analyses revealed that the most common investigated mtDNA variations (> 10% in the control population) at C5178a (in NADH dehydrogenase subunit 2 gene, ND2) and A249d (in the displacement loop region, D-loop)/T6392C (in cytochrome c oxidase I gene, CO1)/G10310A (in ND3) were associated with a reduced risk of severe COVID-19 (OR = 0.590, 95% CI 0.428-0.814, P = 0.001; and OR = 0.654, 95% CI 0.457-0.936, P = 0.020, respectively), while A4833G (ND2), A4715G (ND2), T3394C (ND1) and G5417A (ND2)/C16257a (D-loop)/C16261T (D-loop) were related to an increased risk of severe COVID-19 (OR = 2.336, 95% CI 1.179-4.608, P = 0.015; OR = 2.033, 95% CI 1.242-3.322, P = 0.005; OR = 3.040, 95% CI 1.522-6.061, P = 0.002; and OR = 2.890, 95% CI 1.199-6.993, P = 0.018, respectively).

conclusionsThis is the first study to explore the association of mtDNA variants with individual's risk of developing severe COVID-19. Based on the case-control study, we concluded that the common mtDNA variants at C5178a and A249d/T6392C/G10310A might contribute to an individual's resistance to developing severe COVID-19, whereas A4833G, A4715G, T3394C and G5417A/C16257a/C16261T might increase an individual's risk of developing severe COVID-19.

Indexed as

COVID-19DNA, MitochondrialCase-Control StudiesChinaHumansMitochondriaPhylogenyRisk FactorsDNA, MitochondrialCOVID-19Han ChineseMtDNA variationsRiskSARS-CoV-2

Identifiers

PMID34724985
PMCPMC8558762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.